Biocon Biologics
Kanta Jagannathan currently serves as the GM of Business Development & Licensing for Advanced Markets at Biocon Biologics since December 2023. Prior experience includes a tenure at Viatris from January 2020 to December 2023, where Kanta held the position of General Manager focusing on biosimilars strategy in emerging markets, as well as Deputy General Manager for biosimilars, with responsibilities in project management and marketing of insulins. Prior roles at Mylan involved leadership in North Africa commercial operations and strategic analytics for emerging markets. Kanta's earlier career includes positions at Boehringer Ingelheim, focusing on market access and business development, and at Biocon, concentrating on API business development. Kanta's educational background includes an MBA in Pharma Management and Marketing from SVKM's Narsee Monjee Institute of Management Studies, along with a Bachelor of Pharmacy from the same institution.
This person is not in any teams
This person is not in any offices
Biocon Biologics
8 followers
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Follow-us on Twitter: @BioconBiologics